SCHEMBL2839367

SCHEMBL2839367

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2ccnc(CNCCN3CCC(c4ccccc4)(N4CCCC4)CC3)n2)c(C)c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 5/20 0.32
CASP7 P55210 3/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
CASP1 P29466 1/20 0.32
CASP2 P42575 1/20 0.32
CASP4 P49662 1/20 0.32
CASP9 P55211 1/20 0.32
CASP6 P55212 1/20 0.32
CASP8 Q14790 1/20 0.32
NPY5R Q15761 3/20 0.32
EDNRA P25101 2/20 0.32
HTR7 P34969 2/20 0.31
TMEM97 Q5BJF2 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
NPY1R P25929 1/20 0.31
KCNH2 Q12809 1/20 0.31
HTR1A P08908 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836404 0.99 CASP3 (0.33) CASP3CASP7RAB9ACASP1CASP2
SCHEMBL2830566 0.91 OPRM1 (0.37) CASP3CASP7RAB9ANPC1CASP1
SCHEMBL2835146 0.90 NPY5R (0.33) CASP3CASP7RAB9ANPC1CASP1
SCHEMBL2836449 0.89 OPRM1 (0.37) CASP3CASP7RAB9ACASP1CASP2
SCHEMBL2360725 0.89 HTR7 (0.34) CASP3CASP7RAB9ACASP1CASP2
SCHEMBL2834641 0.88 NPY1R (0.31) NPY5RNPY1R
SCHEMBL2839676 0.87 OPRM1 (0.36) CASP3CASP7RAB9ANPC1CASP1
SCHEMBL2839370 0.86 CASP3 (0.34) CASP3CASP7CASP1CASP2CASP4
SCHEMBL2832094 0.85 OPRM1 (0.37) CASP3CASP7RAB9ACASP1CASP2
SCHEMBL2835614 0.85 NAMPT (0.32) NPY5RNPY1RKCNH2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CASP3 1252/4885CASP7 1641/4885RAB9A 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.